Deciphera Pharmaceuticals, Inc. (DCPH) financial statements (2022 and earlier)

Company profile

Business Address 200 SMITH STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments87136120294197
Cash and cash equivalents87136120294197
Receivables2114   
Inventory, net of allowances, customer advances and progress billings146   
Inventory146   
Other undisclosed current assets21742947371
Total current assets:339584593301198
Noncurrent Assets
Operating lease, right-of-use asset373621
Property, plant and equipment9106131
Long-term investments and receivables429   
Long-term investments429   
Restricted cash and investments3321 
Other noncurrent assets    0
Total noncurrent assets:905829151
TOTAL ASSETS:429642622316199
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3233382314
Accounts payable13122084
Accrued liabilities745149
Employee-related liabilities121713  
Debt  2  
Restructuring reserve21    
Due to related parties   00
Other undisclosed current liabilities443720  
Total current liabilities:9770602314
Noncurrent Liabilities
Long-term debt and lease obligation282916  
Operating lease, liability282916
Liabilities, other than long-term debt   11
Due to related parties   11
Other liabilities   00
Other undisclosed noncurrent liabilities(28)(29) 11 
Total noncurrent liabilities:282916131
Total liabilities:12599763615
Stockholders' equity
Stockholders' equity attributable to parent, including:305544546280184
Common stock1110 
Additional paid in capital1,3591,2981,034575380
Accumulated other comprehensive income000  
Accumulated deficit(1,054)(754)(488)(296)(196)
Other undisclosed stockholders' equity attributable to parent    0
Total stockholders' equity:305544546280184
TOTAL LIABILITIES AND EQUITY:429642622316199

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues964225  
Cost of revenue(3)(0)   
Cost of goods and services sold(3)(0)   
Gross profit:934225  
Operating expenses(393)(313)(226)(104)(51)
Operating loss:(300)(271)(201)(104)(51)
Nonoperating income05841
Other nonoperating income05941
Interest and debt expense  (0)(0)(0)
Loss before gain (loss) on sale of properties:(300)(266)(192)(100)(50)
Other undisclosed net income  00 
Net loss:(300)(266)(192)(100)(50)
Other undisclosed net income attributable to parent    0
Net loss available to common stockholders, diluted:(300)(266)(192)(100)(50)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(300)(266)(192)(100)(50)
Other comprehensive income0    
Comprehensive loss:(300)(266)(192)(100)(50)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (0)0  
Comprehensive loss, net of tax, attributable to parent:(300)(267)(192)(100)(50)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: